StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their price target on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th.

Minerva Neurosciences Stock Performance

Shares of NASDAQ NERV opened at $2.66 on Thursday. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49. The company has a 50 day simple moving average of $3.11 and a two-hundred day simple moving average of $3.52. The company has a market capitalization of $18.60 million, a price-to-earnings ratio of -0.60 and a beta of 0.15.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). On average, analysts forecast that Minerva Neurosciences will post -1.89 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.